Tumour exosomes

Exosomes are extracellular vesicles ranging from 30 to 150nm in diameter that are released from various types of cells, including tumour cells. They can induce apoptosis, modulate the immune system, and function as biomarkers for diagnosis. In addition, as an important component of cell-to-cell communication, exosomes can regulate the tumor microenvironment and are involved in the development, progression, and metastasis processes of numerous cancers1,2.

Tumour-derived exosomes contain proteins, nucleic acids, lipids, and metabolites that can act as effective messengers in the communication between tumor cells and various types of cells, including immune cells, vascular endothelial cells, and mesenchymal cells. Communication among these cells has important effects on tumour biological activities, such as immune regulation, angiogenesis, and epithelial-mesenchymal transition (EMT), which further influence tumour cell growth, proliferation, and metastasis3.

Tumour exosomes may play a dual role in immune regulation. On the one hand, exosomes exert an important effect in promoting antitumor immune responses through their immune activity. Some exosomes released by tumour cells carry tumour-specific antigens, such as CEACAM5, HER2, mesothelin, CD24, and EpCAM, which can activate cytotoxic T cell responses, and induce protective antitumor immune responses. Tumour-derived exosomes can also directly activate NK cells by expressing the stress protein HSP70, which helps elicit antitumor immune responses and promote tumour regression.

On the other hand, some evidence suggests that tumour-derived exosomes can promote cancer progression by suppressing the host immune response. The mechanisms include inhibition of immune cell effectors and activation of suppressor immune cells. Some tumour-derived exosomes carry PD-L1, with IFN-γ increasing the amount of PD-L1 on these exosomes. PD-L1 binds to PD-1 through its extracellular structural domain, which inactivates CD8 T cells, thereby inhibiting CD8 T cell function and promoting tumour growth. Exosomes may also suppress T cell receptor activity or regulate effector T cell transcriptome. In addition, TGF-β from tumour-derived exosomes exerts an inductive effect on Treg cells and blocks IL-2-mediated NK cell activation and decreases NK cell activation receptor expression3-5. Overall, the role of tumour-derived exosomes in the immune response is complex and related to the local microenvironment generated by the tumour itself.

As a leading global supplier of bioreagents and CRO services for the biopharmaceutical field, Sino Biological offers a comprehensive collection of high-quality recombinant proteins and corresponding antibodies to support research on exosomes and tumour immune response.

Cancer progression is closely associated with angiogenesis. Nascent capillaries provide nutrients, oxygen, and growth factors to the tumour and play an important role in tumour cell proliferation and metastasis. Exosomes released from tumour cells, which are involved in tumour angiogenesis, can be taken up by vascular endothelial cells, thereby stimulating angiogenesis. Under hypoxic conditions, exosome production is enhanced. This process is associated with the pro-angiogenic secretory group of endothelial cells3.

Evidence suggests that exosomes play an important role in angiogenesis. Myeloid leukemia-derived exosomes regulate angiogenesis through the enrichment of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). Skin cancer cells secrete exosomes that deliver EGFR to endothelial cells and promote angiogenesis. Moreover, certain tumour-derived exosomes can drive the secretion of pro-angiogenic cytokines, including FGF, G-CSF, TNF-α, VEGF, and more6. Among them, VEGF-A, a member of the VEGF family, plays a key role in tumour angiogenesis. Other members of this family, which include VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PlGF, show affinity to VEGFR. Except for PlGF, other members play important roles in the process of angiogenesis, thereby promoting cancer progression7,8. Sino Biological has developed a comprehensive collection of cytokines and corresponding receptors associated with angiogenesis, which have been validated to be of high purity and activity.

EMT is a cellular process in which epithelial cells lose cell polarity and intercellular adhesion and transform into loosely structured mesenchymal cells. During this process, the expression of epithelial cell markers, such as E-cadherin and β-catenin, is downregulated, whereas that of hypodermal cell markers, such as N-cadherin and vimentin, is upregulated. EMT is associated with cancer progression and induces tumour invasion and metastasis, which promote poor patient prognosis. From the initial activation of the invasive phenotype to metastasis, tumor-derived exosomes play an important role in the induction of tumour-associated EMT9,10.

Tumour-derived exosomes contain EMT-associated inducers, such as TGF-β, TNF-α, IL-6, β-catenin, caveolin-1, and HIF-1α, which contribute to the induction of EMT, enhance cell invasion, and promote tumour cell development and metastasis. Under hypoxic conditions, the release of exosomes from different tumor cells, such as breast and prostate cancer, glioma, and leukemia cells, is increased and can further enhance the occurrence of metastasis through EMT. In addition, exosomes contain nucleic acids, such as DNA, RNA, non-coding RNA, and miRNA, which can be involved in EMT regulation in cancer. The common EMT-related regulatory pathways include the β-catenin, Hippo, and MAPK/ERK pathways. Sino Biological provides EMT-related recombinant proteins and corresponding antibodies products to support exosome and EMT research10,11.

Targeting tumour-derived exosomes may have a positive effect on cancer therapy. Exosomes secreted by malignant cells have a tumour-promoting effect. In general, tumour cells secrete more exosomes than normal cells. These secretomes carry miRNAs, lncRNAs, and proteins that may act as biomarkers for cancer diagnosis and prognostic monitoring4. In addition, exosomes play an important role in resistance to therapy. Exosomes carry a specific set of miRs that can transfer resistant phenotypes to sensitive cancer cells, conferring resistance to chemotherapy and radiation, which is achieved by altering the cell cycle and inducing anti-apoptotic processes. Exosomes may also inhibit the entry of chemotherapeutic agents into target cancer cells, thereby affecting the efficacy of chemotherapy3. Therefore, targeting exosomes may provide a new direction for cancer therapy, and relevant clinical trials are already underway.

Exosomes are biologically active extracellular vesicles containing proteins, nucleic acids, and lipids that mediate cell-to-cell communication. Communication among cells can shape the tumour microenvironment and is critical for tumour growth, invasion, and immune surveillance. Exosomes may function as new biomarkers for cancer diagnosis, therapeutic intervention, and prognostic prediction, which may represent a new opportunity for cancer therapy. In the future, research on exosomes may focus on the purification, characterisation, and compositional assay of exosomes associated with cancer progression5. As a leading global supplier of bioreagents and CRO services for the biopharmaceutical field, Sino Biological is at the forefront of supporting exosome and tumour progression research by providing researchers with a comprehensive range of high-quality reagents and services.

 

References

1. Han, Chen, et al. "Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment." Oncoimmunology 10.1 (2021): 1887552. doi: 10.1080/2162402X.2021.1887552

2. Nicolini, Andrea, Paola Ferrari, and Pier Mario Biava. "Exosomes and cell communication: from tumour-derived exosomes and their role in tumour progression to the use of exosomal cargo for cancer treatment." Cancers 13.4 (2021): 822. doi: 10.3390/cancers13040822

3. Kalluri, Raghu. "The biology and function of exosomes in cancer." The Journal of clinical investigation 126.4 (2016): 1208-1215. doi: 10.1172/JCI81135

4. Liu, Shang-Long, et al. "Exosomes as critical mediators of cell-to-cell communication in cancer pathogenesis and their potential clinical application." Translational Cancer Research 8.1 (2019): 298. doi: 10.21037/tcr.2019.01.03

5. Li, Qiao. "Role of exosomes in cellular communication between tumor cells and the tumor microenvironment." Oncology Letters 24.1 (2022): 1-8. doi: 10.3892/ol.2022.13360

6. Maia, Joana, et al. "Exosome-based cell-cell communication in the tumor microenvironment." Frontiers in cell and developmental biology 6 (2018): 18. doi: 10.3389/fcell.2018.00018

7. Aslan, Cynthia, et al. "Tumor‐derived exosomes: Implication in angiogenesis and antiangiogenesis cancer therapy." Journal of cellular physiology 234.10 (2019): 16885-16903. doi: 10.1002/jcp.28374

8. Olejarz, Wioletta, et al. "Exosomes in angiogenesis and anti-angiogenic therapy in cancers." International Journal of Molecular Sciences 21.16 (2020): 5840. doi 10.3390/ijms21165840

9. Kim, Hyunwoo, et al. "The emerging roles of exosomes as EMT regulators in cancer." Cells 9.4 (2020): 861. doi: 10.3390/cells9040861

10. Wu, Miaowei, et al. "Emerging roles and therapeutic value of exosomes in cancer metastasis." Molecular cancer 18.1 (2019): 1-11. doi: 10.1186/s12943-019-0964-8

11. Vella, Laura Jayne. "The emerging role of exosomes in epithelial–mesenchymal-transition in cancer." Frontiers in oncology 4 (2014): 361. doi: 10.3389/fonc.2014.00361